OncoTelic Overview

  • Founded
  • 2015
  • Status
  • Public
  • Employees
  • 13
  • Stock Symbol
  • MATN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.22
  • (As of Wednesday Closing)

OncoTelic General Information


Mateon Therapeutics Inc is an oncology company focusing on therapies against cancers and infectious diseases. It has three business segments namely, PointR; Mateon/Oxigene; and Oncotelic. PointR is the developer of vision grid/cluster computing/AI to support drug development. Mateon/Oxigene develops a Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma and OXi4503 rare pediatric designation for pediatric ALL. Oncotelic consists development of OT-101 - antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 against pancreatic cancer, glioblastoma, and melanoma. The firm is also developing Artemisinin which is approved by India and in phase 4 clinical trial against COVID.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • 29397 Agoura Road
  • Suite 107
  • Agoura Hills, CA 91301
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTelic Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.22 $0.22 $0.08 - $0.38 $19.5M 89.6M 323K -$0.12

OncoTelic Financials Summary

In Thousands,
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 18,345 14,796 2,131 1,991
Revenue 1,741 0 0 0
EBITDA (6,973) (5,828) (2,751) (13,838)
Net Income (9,544) (6,638) (2,737) (13,812)
Total Assets 24,629 23,685 799 1,172
Total Debt 3,022 1,501 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoTelic Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.

Request a free trial

OncoTelic Executive Team (11)

Name Title Board Seat Contact Info
Amit Shah Chief Financial Officer
Chulho Park Ph.D Co-Founder & Chief Business Officer
Frederick Driscoll Chief Executive Officer & Board Member
You’re viewing 3 of 11 executive team members. Get the full list »

OncoTelic Board Members (8)

Name Representing Role Since
Anthony Maida Ph.D Self Board Member 000 0000
Frederick Driscoll Self Chief Executive Officer & Board Member 000 0000
You’re viewing 2 of 8 board members. Get the full list »

OncoTelic Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoTelic Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 25-Apr-2019 000000000000000000 Drug Discovery 00000 00000 00.0
To view OncoTelic’s complete acquisitions history, request access »